Bioxytran, Inc.
BIXT
Rank in Stocks
#31994
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development... Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Share Price
$0.022425
Last synced: 2026-11-09
Market Cap
$2.22M
Change (1 day)
-2.92%
Change (1 year)
-67.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Bioxytran, Inc. (BIXT)
Category
Healthcare
EPS for Bioxytran, Inc. (BIXT)
EPS as of June 2026 TTM: $-0.03
According to Bioxytran, Inc.'s latest financial reports, its current EPS (TTM) is $-0.03. At the end of 2025 the company had an EPS of $-0.02, equal to its 2024 EPS of $-0.02.
EPS history for Bioxytran, Inc. from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.03 | 60.50% |
| 2025 | $-0.02 | 35.09% |
| 2024 | $-0.02 | -46.39% |
| 2023 | $-0.03 | 49.07% |
| 2022 | $-0.02 | -47.68% |
| 2021 | $-0.04 | 2.25% |
| 2020 | $-0.04 | 63.93% |
| 2019 | $-0.02 | 597.14% |
| 2018 | 0.00 | -98.54% |
| 2017 | $-0.24 | -69.62% |
| 2016 | $-0.79 | -87.36% |
| 2015 | $-6.25 | -31.09% |
| 2014 | $-9.07 | -36.26% |
| 2013 | $-14.23 | -45.44% |
| 2012 | $-26.08 | -48.10% |
| 2011 | $-50.25 | 359.32% |
| 2010 | $-10.94 | -66.19% |
| 2009 | $-32.36 | 1,035.44% |
| 2008 | $-2.85 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -48,885.05% |
US
|
|
| $-7.07 | 21,924.92% |
US
|
|
| $-5.29 | 16,379.75% |
AU
|
|
| $12.88 | -40,224.92% |
BE
|
|
| $21.56 | -67,265.11% |
NL
|
Questions about Bioxytran, Inc.'s earnings per share (EPS)
What is Bioxytran, Inc.'s earnings per share (EPS)?
Bioxytran, Inc.'s earnings per share (EPS) over the last twelve months is $-0.03, as of Jun 2026.
What was Bioxytran, Inc.'s earnings per share (EPS) in 2025?
In 2025, Bioxytran, Inc.'s earnings per share (EPS) was $-0.02, compared with $-0.02 in 2024.
How has Bioxytran, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Bioxytran, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.02) and lowest in 2021 ($-0.04).
How does Bioxytran, Inc.'s earnings per share (EPS) compare with similar companies?
Bioxytran, Inc.'s earnings per share (EPS) ($-0.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.